These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2899641)

  • 21. [Chemical structure and toxicodynamic properties of phenoxycarboxylic acid derivatives. III. The course of absorption into the blood and the measurement of the urinary excretion of phenoxyacetic and phenoxypropionic acid derivatives].
    Seńczuk W; Pogorzelska H
    Rocz Panstw Zakl Hig; 1981; 32(5-6):419-26. PubMed ID: 7344054
    [No Abstract]   [Full Text] [Related]  

  • 22. [Microbiological transformation of herbicides in co-oxidation conditions].
    Skriabin GK; Golovleva LA; Strekozov BP; Pribud'ko NV
    Izv Akad Nauk SSSR Biol; 1974; (3):353-60. PubMed ID: 4218859
    [No Abstract]   [Full Text] [Related]  

  • 23. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):732-8. PubMed ID: 6655566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A renal mechanism for the clofibric acid-probenecid interaction.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):739-42. PubMed ID: 6655567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.
    Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP
    Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 27. [Peroxisome induction with clofibric acid and bis(p-chlorophenoxy)acetic acid (proceedings)].
    Zipper J; Janowski K; Göres E
    Pharmazie; 1979; 34(5-6):366-7. PubMed ID: 515158
    [No Abstract]   [Full Text] [Related]  

  • 28. Plafibride (ITA 104).
    Arzneimittelforschung; 1981; 31(10a):1781-866. PubMed ID: 7198454
    [No Abstract]   [Full Text] [Related]  

  • 29. Activation of hypolipidaemic drugs to acyl-coenzyme A thioesters.
    Bronfman M; Amigo L; Morales MN
    Biochem J; 1986 Nov; 239(3):781-4. PubMed ID: 3827829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
    Meffin PJ; Zilm DM
    J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR; Chasseaud LF; Taylor T; Schatton W
    Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism].
    Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700
    [No Abstract]   [Full Text] [Related]  

  • 34. [Etofibrate lowers the atherosclerosis index].
    Mertz DP; Suermann I; Göhmann E
    Med Klin; 1981 Mar; 76(6):166-8. PubMed ID: 7231329
    [No Abstract]   [Full Text] [Related]  

  • 35. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
    Rowe BJ; Meffin PJ
    J Pharmacol Exp Ther; 1984 Jul; 230(1):237-41. PubMed ID: 6747828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Plafibride and vascular insufficiency of the lower limbs].
    Soringer Escofet FJ; Esteva de Antonio I
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999856
    [No Abstract]   [Full Text] [Related]  

  • 37. Bezafibrate does not influence the QT interval in man.
    Olsson AG; Ekelund LG; Lang PD; Vollmar J
    J Cardiovasc Pharmacol; 1983; 5(2):341-2. PubMed ID: 6188913
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacologic therapy of arteriosclerosis: current possibilities].
    Priego JG; Díaz Méndez M
    Med Clin (Barc); 1984 Oct; 83(10):431-2. PubMed ID: 6503408
    [No Abstract]   [Full Text] [Related]  

  • 39. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 40. [Toxic myopathy due to hypolipemic agents].
    Bourrier P; Subra JF; Chennebault JM; Spiesser R; Laine P
    Therapie; 1990; 45(4):360. PubMed ID: 2399525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.